Name:
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: A patient perspective of the ARAMIS trial
Description:
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: A patient perspective of the ARAMIS trial
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/cb99c80d-865a-4d36-b1c4-4a0d2bbe0827/videoscrubberimages/Scrubber_78.jpg
Duration:
T00H01M34S
Embed URL:
https://stream.cadmore.media/player/cb99c80d-865a-4d36-b1c4-4a0d2bbe0827
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/cb99c80d-865a-4d36-b1c4-4a0d2bbe0827/ARAMIS PLSP_VJBM-2021-0003.mp4?sv=2019-02-02&sr=c&sig=ioOZz314ffVKb%2BxGl%2BPW7QSkHHzCQQ4ju%2ByhmTXuqBQ%3D&st=2024-12-23T07%3A00%3A36Z&se=2024-12-23T09%3A05%3A36Z&sp=r
Upload Date:
2022-06-21T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
NARRATOR: Non-metastatic castration-resistant prostate cancer, known as nmCRPC, is a type of prostate cancer that has not spread to other parts of the body. Prostate specific antigen, or PSA levels, continue to rise despite surgery and hormone therapy, known as ADT, which is used to lower testosterone levels. Because this type of prostate cancer no longer responds to initial ADT, novel drugs are needed to help patients live longer with good quality of life.
NARRATOR: The ARAMIS trial investigated a new drug, darolutamide. Darolutamide works by binding to androgen receptors and blocking the testosterone signal. This helps slow tumor growth. The phase three ARAMIS trial recruited patients with nmCRPC. They either received darolutamide or placebo in addition to ADT. The ARAMIS results show that those who received darolutamide lived longer and risk of death was decreased by 31%.
NARRATOR: Darolutamide also delayed time to worsening pain, needing chemotherapy, or experiencing cancer related bone fractures. And the frequency of adverse events was similar compared to placebo. A summary of the study was written in collaboration with prostate cancer patients. They explained how scientists, doctors, and patients need to work together, and the positive outcomes of the trial drug.
NARRATOR: Darolutamide is effective and well tolerated in patients with nmCRPC. It helps them live longer so they can enjoy life again.
